Open an account

Ekso Bionics Holdings

CHRN · NASDAQ

$15.76+$0.79 (+5.28%)TodayMarket closed ·
Prev close $14.97

About CHRN

Ekso Bionics Holdings, Inc. designs, develops, and markets exoskeleton products. Its exoskeleton technology serves people with physical disabilities or impairments in both physical rehabilitation and mobility. It operates as one segment with two markets: Enterprise Health and Personal Health. Its products include EksoNR, which is a wearable robotic exoskeleton designed for a rehabilitation setting; Ekso Indego Therapy is a modular, adjustable, lightweight, lower limb-powered exoskeleton; Ekso Indego Personal is a lower limb orthosis; Ekso Nomad is a power Knee Ankle Foot Orthosis, and Ekso EVO is a wearable upper body exoskeleton. It enables individuals with neurological conditions affecting gait, including acquired brain injury (ABI) and spinal cord injury (SCI), to rehabilitate, stand and walk again. Additionally, the devices assist people with a variety of upper extremity disabilities and enable industrial employees to perform challenging repetitive tasks for extended periods.

Employees
50
Headquarters
San Rafael California, California
Listed
Apr 10, 2013
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
eksobionics.com

CHRN key statistics

Market cap
2.30B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
139.51K
Volume
106.66K
Open price
$14.68
High today
$16.19
Low today
$14.67
52 Week high
$30.00
52 Week low
$3.50

Ekso Bionics Holdings (CHRN) at a glance

Ekso Bionics Holdings (CHRN) last traded at $15.76, with a market cap of 2.30B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $14.67 and $16.19. The current price is 7.5% above the day's low and 2.6% below its high.

Volume so far is 106.66K shares, below the average of 139.51K shares a day.

Over the past year Ekso Bionics Holdings has ranged from $3.50 to $30.00, and now sits 46% of the way up that range.

Ekso Bionics Holdings met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q1 FY27 it reported -$0.29 per share against an estimate of -$0.0918.

The average analyst price target is $21.17, 34.3% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 4 analystsAvg $21.17
Low
$9.60
Now
$15.76
High
$33.60

CHRN earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 23.4% on average.

  1. Q3 FY24: reported -$1.50 per share against an estimate of -$1.61
  2. Q4 FY24: reported -$2.10 per share against an estimate of -$1.22
  3. Q1 FY25: reported -$1.80 per share against an estimate of -$1.68
  4. Q2 FY25: reported -$1.24 per share against an estimate of -$1.38
  5. Q3 FY25: reported -$0.54 per share against an estimate of -$1.17
  6. Q4 FY25: reported -$1.33 per share against an estimate of -$0.2907
  7. Q1 FY26: reported -$2.04 per share against an estimate of -$0.2346
  8. Q1 FY27: reported -$0.29 per share against an estimate of -$0.0918

CHRN news

  • Akanksha Bakshi

    ChronoScale Expands AI Pipeline With $1 Billion Revenue Run Rate In Sight

  • 10 Information Technology Stocks Moving In Thursday's Intraday Session

  • 12 Information Technology Stocks Moving In Wednesday's After-Market Session

Similar companies

Companies in the same industry as Ekso Bionics Holdings

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.